ARMP · Armata Pharmaceuticals, Inc.
$3.52
+0.21 (+6.34%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash and cash equivalents of $24.0 million as of June 30, 2026 will not be sufficient to enable us to complete all necessary development of any potential product candidates and fund our operations for the next 12 months from the date the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. These circumstances raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$133.67M
Shares
37.18M
Volume · Oct 2
124.49K
Avg daily vol (3M)
213.24K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.31
Open$3.67
Day$3.28–3.78
52W close$2.96–14.80
Avg vol 30d287K
Short int963K · 2.6% float · 1.7d
Short vol69%
Last earningsNov 25, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+11.8%
Trailing year
Short interest
2.6%
Latest settlement · 1.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−55%
below
Price vs 50-day avg
−30%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−40%
trailing
6-month return
−70%
trailing
YTD return
−47%
this year
Relative strength
−83%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+18% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.59% of float · ▲ +8.8% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
53 holders — near 3-yr high, broad support
Squeeze score
46
elevated · 0–100
Fundamentals
EPS growth
−439%
Y/Y
Free cash flow
$-26.3M
Quant / Vol
risk profile
Volatility
151%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
14.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−55%
Bearish
Price vs 50-day avg
−30%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+18% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.59% of float · ▲ +8.8% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
53 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 3%
Range high $15
vs 200-day avg -55%
vs 50-day avg -30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARMP
this stock
Armata Pharmaceuticals, Inc.
|
$133.67M | -47.3% | — | — | 2.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +540.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARMP | -8.6% | -40.1% | -70.2% | -9.8% | -47.3% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -8.1% | -40.0% | -82.7% | -10.0% | -59.3% |